

Phytotherapy's Impact on Immune Regulation in Degenerative Diseases

Desi Nadya Aulena^{1*}, Iqbal Julian²

¹ Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Pancasila, Jakarta, Indonesia.

² Department of Biomedical and Clinical Pharmacy, Faculty of Pharmacy, Universitas Pancasila, Jakarta, Indonesia.

*Corresponding Author: desi.nadya@univpancasila.ac.id

Received: 15 August 2025 / Accepted: 29 September 2025

ABSTRACT: This literature review looks at how phytotherapy affects immune regulation in degenerative diseases like neurodegenerative, autoimmune, and metabolic disorders. We begin by outlining a theoretical framework that explains how chronic inflammation, caused by pathways such as NF- κ B and the NLRP3 inflammasome, plays a central role in these conditions. Next, we explore how different phytochemicals, including flavonoids, stilbenes, and phenolic acids, achieve their therapeutic effects by influencing these important inflammatory pathways, lowering cytokine production, and offering antioxidant support. The review applies this knowledge to specific diseases, emphasizing how compounds like curcumin and resveratrol may help reduce neuroinflammation and improve immune balance. Finally, we discuss the main challenges related to bioavailability and standardization, suggesting future research paths to realize the full potential of these natural compounds as effective strategies for managing chronic degenerative conditions.

KEYWORDS: Phytotherapy; Immune Regulation; Degenerative Diseases; Inflammation; Phytochemicals.

1. INTRODUCTION

The rise of age-related and lifestyle-related degenerative diseases, like Alzheimer's disease, rheumatoid arthritis, and some forms of metabolic syndrome, poses a significant challenge to global public health. These serious conditions vary in their clinical signs but share a common issue: chronic, low-grade inflammation and serious immune dysfunction. This ongoing inflammatory response, often called "metaflammation" in metabolic situations or "neuroinflammation" in the brain, is not just a result of the disease but a major factor in its progression. It leads to ongoing tissue damage, loss of function, and a lower quality of life. Despite notable improvements in conventional medicine, current treatments often only relieve symptoms, can have serious side effects, or do not stop the disease from progressing. This highlights the urgent need for new and effective treatment options [1].

In this situation, phytotherapy, which involves using plant-based compounds for medicinal purposes, has become a promising area of research. For thousands of years, traditional medicine systems worldwide have used herbal remedies to treat various issues, including those related to inflammation. Modern studies are starting to reveal the complex ways that these plant-based compounds, called phytochemicals, work to provide their benefits. Unlike synthetic drugs that target a single issue, many phytochemicals have multiple effects that influence a variety of biological processes at once. Increasing evidence shows that these compounds can act as strong immune regulators, helping to restore immune balance by targeting crucial signalling molecules and cellular mechanisms that are disrupted in degenerative diseases [2].

This literature review will summarize and critically assess the current scientific knowledge about how phytotherapy affects immune regulation in degenerative diseases. We will look at how different types of phytochemicals, such as flavonoids, terpenoids, and alkaloids, affect important inflammatory pathways like NF- κ B and the NLRP3 inflammasome. The review will connect this understanding to specific diseases, exploring the potential of phytotherapy in neurodegenerative conditions like Alzheimer's and inflammatory diseases like rheumatoid arthritis. By bringing together the existing knowledge, this review provides an extensive overview of the field, identifies gaps in current knowledge, and suggests future research directions.

How to cite this article: Aulena DN, Julian I. Phytotherapy's Impact on Immune Regulation in Degenerative Diseases. JNPDD. 2025; 3(1): 8-15.

The main point of this review is that phytochemicals are a valuable and underused resource of therapeutic agents that can help restore immune balance, offering a way to modify the disease for various degenerative conditions.

2. THE INTERPLAY OF IMMUNITY AND DEGENERATION

The basis of this literature review focuses on the essential connection between immune system function and the development of degenerative diseases. A healthy immune system keeps homeostasis, which is a state of balance in the body, by responding effectively to threats and resolving inflammation after the threat is dealt with. This delicate balance is maintained through a complex network of cells and signalling molecules.

2.1. Immune System Fundamentals and Chronic Inflammation

The immune system has two main branches: innate and adaptive. The innate branch provides a fast, non-specific response, using cells like macrophages and neutrophils to engulf and destroy pathogens. The adaptive branch, which includes T cells and B cells, offers a specific, long-lasting memory response. Normally, a temporary acute inflammatory response is essential for healing. However, in degenerative diseases, this response can become chronic, resulting in a persistent low-grade inflammatory state. This may be caused by various factors, such as ongoing tissue damage, buildup of misfolded proteins, and genetic factors. Chronic inflammation can have both positive and negative effects. While it begins as a protective mechanism, its unchecked persistence can create a cycle of tissue damage and dysfunction. This is a key feature of conditions like Alzheimer's, Parkinson's, and rheumatoid arthritis [3].

2.2. Key Molecular Pathways of Immune Dysregulation

The shift from a protective to a harmful inflammatory state is driven by the disruption of important molecular signaling pathways. Phytochemicals influence these pathways. The three of the most significant ones are NF- κ B, STAT 3, and NLRP3 inflammasome.

Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF- κ B) is a key regulator of the inflammatory response. In its inactive state, NF- κ B is kept in the cytoplasm. When it receives pro-inflammatory signals like TNF- α , it activates and moves to the nucleus. There, it starts the transcription of hundreds of genes involved in inflammation, including pro-inflammatory cytokines, chemokines, and adhesion molecules. Ongoing activation of NF- κ B is a major part of many degenerative diseases [4].

As a transcription factor, STAT3 (Signal Transducer and Activator of Transcription 3) has a dual role in both normal cell processes and disease. Ongoing activation of the IL-6/JAK/STAT3 signalling pathway is a key aspect of many degenerative conditions. When STAT3 is overactivated, it encourages cell growth and survival. It also increases the expression of pro-inflammatory genes, which helps sustain chronic inflammation [5].

NLRP3 Inflammasome is a multi-protein complex in the innate immune system. When triggered by various stimuli, including substances from pathogens and danger signals from within the body like uric acid crystals or amyloid-beta plaques, the NLRP3 inflammasome comes together. This process activates caspase-1, which then cuts the pro-inflammatory cytokines IL-1 β and IL-18 into their active forms. This starts a strong inflammatory response. Unchecked activation of the NLRP3 inflammasome is closely linked to the progression of many inflammatory and neurodegenerative diseases [6].

Understanding these pathways is important because they provide molecular targets for the phytochemicals discussed in this review. By changing these pathways, phytotherapy offers a promising way to restore immune regulation and fight degenerative processes.

3. Phytotherapy: A Deeper Look

Phytotherapy is a broad and varied field, using many different plant species, each with its own unique bioactive compounds. The healing potential of these plant-based agents comes from their ability to affect human physiology through their phytochemicals.

3.1 Key Phytochemical Classes with Immunomodulatory Effects

Phytochemicals are generally divided into several major classes based on their chemical structures. While there are thousands of these compounds, a few key classes have been studied in depth for their strong effects on the immune system.

Phenolic compounds are one of the largest and most studied groups. They have at least one aromatic ring with one or more hydroxyl groups. Key subgroups include: (1) Flavonoids: Found in fruits, vegetables, and tea. Quercetin, from apples and onions, and catechins, from green tea, are well-known examples [7]. (2) Stilbenes: Best known for Resveratrol, a compound in grapes and red wine, it has been studied a lot for its anti-inflammatory and antioxidant properties [8]. (3) Phenolic acids: This group includes curcumin from turmeric and ellagic acid. Curcumin has received a lot of attention because of its strong anti-inflammatory effects [9].

Terpenoids are a large and varied group of organic compounds that come from five-carbon isoprene units. They are responsible for the distinct smells found in many plants [10]. Key subgroups include: (1) Monoterpenes and sesquiterpenes are found in essential oils (e.g., in lemon or rosemary) [11]. (2) Diterpenoids include compounds such as artemisinin, which is known for its anti-malarial properties, and its potential as an anti-inflammatory agent [12].

A group of natural organic compounds that contain at least one nitrogen atom is called alkaloids. An example is berberine, which comes from barberry. Berberine can influence immune responses and metabolic pathways [13].

Complex carbohydrates found in plants and fungi. Polysaccharides from medicinal mushrooms (e.g., shiitake and reishi) stimulate the immune system and are used in traditional medicine for their immunomodulatory effects [14].

3.2 Mechanisms of Action: How Phytochemicals Modulate Immunity

The effectiveness of these phytochemicals comes from their ability to interact with specific molecular targets. This interaction helps regulate the immune response. Their mechanisms of action are often pleiotropic, which means a single compound can influence multiple pathways at the same time.

Many phytochemicals directly reduce the production of pro-inflammatory cytokines like TNF- α , IL-1 β , and IL-6. For instance, curcumin and resveratrol are strong inhibitors of these signalling molecules. They disrupt the inflammatory process right at its source [15].

Phytochemicals can affect how immune cells work. They can slow down the growth of T-cells, lessen the inflammatory activity of macrophages, and encourage the development of T-regulatory cells (Tregs). These cells are important for maintaining immune tolerance. For example, some flavonoids can stop B cells and macrophages from activating, which lowers the production of inflammatory substances [16].

Many degenerative diseases are linked to high levels of oxidative stress, which causes inflammation. A large number of phytochemicals, especially phenolic compounds, are strong antioxidants that neutralize free radicals and lessen oxidative damage. By lowering oxidative stress, they also reduce the inflammatory burden on tissues [17].

The most important mechanism involves directly targeting the key molecular pathways mentioned earlier. For instance, many phytochemicals, like curcumin and quercetin, directly block the NF- κ B pathway. This prevents the transcription of pro-inflammatory genes. Likewise, compounds such as resveratrol can inhibit the assembly and activation of the NLRP3 inflammasome. This action stops the maturation of the highly inflammatory cytokines IL-1 β and IL-18 [18].

Table 1. Key Phytochemicals and Their Immunomodulatory Effects

Phytochemical	Primary Source(s)	Key Immunomodulatory Mechanism(s)	Example of a Degenerative Disease Target
Curcumin	Turmeric	Inhibits NF- κ B, suppresses cytokine production [19]	Rheumatoid Arthritis, Alzheimer's Disease
Resveratrol	Grapes, Berries	Inhibits NLRP3 inflammasome, antioxidant [20]	Alzheimer's Disease, Metabolic Syndrome
Quercetin	Apples, Onions	Reduces T-cell proliferation, antioxidant [21]	Rheumatoid Arthritis, Type 2 Diabetes
Berberine	Barberry	Activates AMPK, inhibits inflammatory pathways [22]	Type 2 Diabetes

4. Disease-Specific Analysis

The therapeutic potential of phytotherapy is best shown through its use in specific degenerative diseases. By targeting the common inflammatory and immune regulation pathways, phytochemicals could change disease progression in various conditions.

4.1. Neurodegenerative Diseases (e.g., Alzheimer's Disease and Parkinson's Disease)

Neurodegenerative diseases involve the gradual loss of neurons in the central nervous system, mostly due to long-lasting inflammation in the brain. This condition features ongoing activation of immune cells in the brain, mainly microglia. This activation results in the release of pro-inflammatory cytokines and the buildup of harmful protein clusters [23].

Alzheimer's disease (AD) is marked by the buildup of amyloid-beta ($A\beta$) plaques and tau tangles. When microglia are constantly activated by $A\beta$ plaques, they release inflammatory substances that can further harm the neurons. Curcumin and resveratrol are two well-studied phytochemicals. They can cross the blood-brain barrier and have been shown in preclinical studies to inhibit microglial activation; reduce the production of pro-inflammatory cytokines like TNF- α and IL-1 β ; promote the clearing of amyloid-beta plaques; and activate the Nrf2 pathway, which is a key regulator of the antioxidant response, thus protecting neurons from oxidative stress [24].

Parkinson's disease (PD) involves the loss of dopaminergic neurons in the substantia nigra. Neuroinflammation caused by activated microglia and astrocytes plays a significant role in this neuronal loss. Research on compounds like quercetin and epigallocatechin-3-gallate (EGCG) from green tea has shown they can suppress the inflammatory response in the brain and protect dopaminergic neurons from damage [25].

4.2. Autoimmune and Inflammatory Degenerative Diseases (e.g., Rheumatoid Arthritis)

Rheumatoid Arthritis (RA) is a long-term autoimmune disease that causes inflammation throughout the body. This inflammation damages the joints. The immune system incorrectly attacks the body's tissues, resulting in swelling of the synovial membrane, harm to the cartilage, and erosion of the bone. The inflammatory process in RA relies significantly on pro-inflammatory cytokines, such as TNF- α , IL-1 β , and IL-6. It also depends on T-cell activation and the growth of synovial fibroblasts.

Phytochemicals that focus on these pathways are very interesting [26]. Curcumin has been widely researched for its ability to block the NF- κ B pathway. This action reduces the expression of TNF- α and other inflammatory genes [27]. Quercetin stops T cells from activating and lowers the production of inflammatory substances. These substances are important in causing joint damage [28]. Berberine has shown benefits by lowering inflammation markers and improving symptoms in animal models of RA [29].

4.3. Metabolic Degenerative Diseases (e.g., Type 2 Diabetes)

Type 2 diabetes (T2D) is not only a metabolic disorder. It is also seen as a low-grade chronic inflammatory disease. This condition of "metaflammation," caused by excess nutrients and problems with fat cells, contributes to insulin resistance and the failure of pancreatic beta cells [30]. Chronic inflammation disrupts the insulin signalling pathway, causing cells to respond less to insulin.

Curcumin and resveratrol have been proven to increase insulin sensitivity by blocking the NF- κ B and JNK pathways, which inflammatory signals activate [31,32]. Berberine has gained a lot of attention for its ability to activate AMPK [33], a key metabolic regulator. This activation leads to better glucose uptake and lower inflammation. Therefore, it could be a useful treatment for managing both metabolic and inflammatory aspects of T2D.

Table 2. Summary of Preclinical and Clinical Evidence

Phytochemical	Disease	Key Preclinical Findings	Key Clinical Findings (if any)
Curcumin	Alzheimer's	Reduced A β plaques in mice, inhibited microglial activation [34]	Limited clinical data, poor bioavailability is a challenge
Resveratrol	Type 2 Diabetes	Improved insulin sensitivity in animal models, reduced inflammation [35]	Mixed results, some trials show moderate improvement in glycaemic control
Berberine	Type 2 Diabetes	Improved glucose uptake, reduced inflammatory markers in animals [36]	Several clinical trials show efficacy similar to metformin

5. Challenges and Future Directions

Although phytotherapy has great potential for treating degenerative diseases, the field faces several important challenges. These challenges must be addressed to turn promising preclinical results into effective clinical treatments. Recognizing these limitations is essential for a fair and thorough review.

5.1. Challenges in Research and Clinical Application

Many phytochemicals face a big challenge with low bioavailability. Compounds like curcumin are not well absorbed by the body, get broken down quickly, and are eliminated fast [37]. As a result, a large oral dose is needed to reach a therapeutic level. This can limit effectiveness and lead to possible gastrointestinal side effects. Future research should aim to improve absorption using methods like nanocarriers, liposomes, and other formulation technologies.

The chemical makeup of a plant extract can change a lot based on the plant species, growing conditions, harvest time, and processing methods. This lack of standardization makes it hard to compare results from different studies and ensures consistent product quality [38]. Developing strong analytical methods and strict quality control guidelines is vital for phytotherapy.

While most phytochemicals are generally regarded as safe, some can cause side effects, especially at high doses or when taken with other medications. For example, certain compounds can interact with drug-metabolizing enzymes, like the cytochrome P450 system, and potentially change how conventional drugs are processed. More research is needed to identify the long-term safety profiles and possible interactions between drugs and herbs.

Most research on the immunomodulatory effects of phytotherapy in degenerative diseases has been done using *in vitro* (cell culture) or *in vivo* (animal) models. There is a significant need for well-designed, randomized, double-blind, placebo-controlled clinical trials to confirm the efficacy, safety, and proper dosing of these compounds in human patients.

5.2. Future Directions for Research

Future research should not just look at single compounds. It should investigate the combined effects of multiple phytochemicals. Whole plant extracts may offer greater therapeutic benefits than isolated compounds due to the actions of their various components. Studying these interactions may lead to more effective and balanced treatment strategies.

Using proteomics, metabolomics, and transcriptomics can help us understand how phytochemicals impact biological systems. These technologies can identify new molecular targets, clarify complex signalling pathways, and find new biomarkers for responses to phytotherapy.

As we learn more about genetic and epigenetic factors in degenerative diseases, a personalized approach to phytotherapy may become possible. Future research should explore how a person's genetic makeup affects their response to specific phytochemicals, leading to more targeted and effective treatments.

More research is needed to examine how phytochemicals can cross the blood-brain barrier and influence neuroinflammatory pathways in humans. Developing imaging techniques and biomarkers to track neuroinflammation is key in this area.

6. CONCLUSION

The evidence reviewed here highlights the varied effects of phytotherapy on immune regulation in degenerative diseases. Phytochemicals are not just inactive plant compounds. They are powerful bioactive agents that can influence the key pathways related to chronic inflammation and tissue breakdown. For instance, they inhibit major inflammatory regulators like NF- κ B, suppress important cytokines, and effectively scavenge free radicals. This provides a multi-target method for restoring immune balance.

Our analysis showed that this understanding has real therapeutic potential across a range of conditions. In neurodegenerative diseases, phytochemicals such as curcumin and resveratrol can help reduce neuroinflammation and protect sensitive neurons. In autoimmune diseases like rheumatoid arthritis, their ability to inhibit systemic inflammatory mediators may reduce joint damage. In metabolic diseases, compounds like berberine target the root cause of insulin resistance by addressing chronic metaflammation.

In summary, phytotherapy is a promising area in modern medicine that remains largely unexplored. While there are significant challenges, particularly related to bioavailability and the need for thorough clinical testing, its potential is clear. The future of phytotherapy involves using new technologies to tackle these challenges, moving beyond single-compound research to investigate synergistic effects, and adopting a personalized treatment approach. By harnessing nature's power and confirming its effectiveness through strong scientific research, we can develop a new class of therapies that effectively modify diseases and are also well-tolerated, providing new hope for those affected by the ongoing progression of degenerative diseases.

Acknowledgements: None

Author contributions: Concept – D.N.A., I.J.; Design – D.N.A., I.J.; Supervision – I.J.; Resources – D.N.A., I.J.; Materials – D.N.A., I.J.; Data Collection and/or Processing – D.N.A., I.J.; Analysis and/or Interpretation – D.N.A., I.J.; Literature Search – D.N.A., I.J.; Writing – D.N.A., I.J.; Critical Reviews – D.N.A., I.J.

Conflict of interest statement: The authors declared no conflict of interest.

REFERENCES

- [1] W. C. Chong *et al.*, "The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome: a potential therapeutic target for inflammatory disorders," *Clin & Trans Imm*, vol. 10, no. 2, Jan. 2021, doi: 10.1002/cti2.1247.
- [2] H. Kang, "MicroRNA-Mediated Health-Promoting Effects of Phytochemicals," *IJMS*, vol. 20, no. 10, p. 2535, May 2019, doi: 10.3390/ijms20102535.
- [3] K. Gąsiorowski, G. E. Barreto, V. Echeverria, J. Leszek, and B. Brokos, "RAGE-TLR Crosstalk Sustains Chronic Inflammation in Neurodegeneration.," *Mol Neurobiol*, vol. 55, no. 2, pp. 1463–1476, Feb. 2017, doi: 10.1007/s12035-017-0419-4.
- [4] G. Kannan, B. M. Paul, and P. Thangaraj, "Stimulation, regulation, and inflammaging interventions of natural compounds on nuclear factor kappa B (NF- κ B) pathway: a comprehensive review.," *Inflammopharmacol*, vol. 33, no. 1, pp. 145–162, Jan. 2025, doi: 10.1007/s10787-024-01635-4.
- [5] M. A. Samad *et al.*, "STAT3 Signaling Pathway in Health and Disease.," *MedComm*, vol. 6, no. 4, Mar. 2025, doi: 10.1002/mco2.70152.

- [6] C. Paget, E. Doz-Deblauwe, N. Winter, and B. Briard, "Specific NLRP3 Inflammasome Assembling and Regulation in Neutrophils: Relevance in Inflammatory and Infectious Diseases," *Cells*, vol. 11, no. 7, p. 1188, Apr. 2022, doi: 10.3390/cells11071188.
- [7] M. Latos-Brozio and A. Masek, "Structure-Activity Relationships Analysis of Monomeric and Polymeric Polyphenols (Quercetin, Rutin and Catechin) Obtained by Various Polymerization Methods," *Chemistry & Biodiversity*, vol. 16, no. 12, Nov. 2019, doi: 10.1002/cbdv.201900426.
- [8] Radeva and K. Yoncheva, "Resveratrol-A Promising Therapeutic Agent with Problematic Properties," *Pharmaceutics*, vol. 17, no. 1, p. 134, Jan. 2025, doi: 10.3390/pharmaceutics17010134.
- [9] D. K. Khatri and A. R. Juvekar, "Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid," *Phcog Mag*, vol. 12, no. Suppl 2, p. 116, May 2016, doi: 10.4103/0973-1296.182168.
- [10] Z. Qiao, H. Hu, X. Yuan, B. Yan, S. Shi, and L. Chen, "An Update on the Function, Biosynthesis and Regulation of Floral Volatile Terpenoids," *Horticulturae*, vol. 7, no. 11, p. 451, Nov. 2021, doi: 10.3390/horticulturae7110451.
- [11] D. Cox-Georgian, C. Dona, N. Ramadoss, and C. Basu, "Therapeutic and Medicinal Uses of Terpenes," vol. 3, no. 5, Springer, 2019, pp. 333–359. doi: 10.1007/978-3-030-31269-5_15.
- [12] Y. Xiong and J. Huang, "Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment," *Chin Med*, vol. 16, no. 1, Aug. 2021, doi: 10.1186/s13020-021-00489-0.
- [13] C. Caliceti, A. F.G Cicero, S. Spinozzi, P. Franco, and A. Roda, "Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders," *CMC*, vol. 23, no. 14, pp. 1460–1476, May 2016, doi: 10.2174/0929867323666160411143314.
- [14] B. Balakrishnan et al., "Combining the Anticancer and Immunomodulatory Effects of Astragalus and Shiitake as an Integrated Therapeutic Approach," *Nutrients*, vol. 13, no. 8, p. 2564, July 2021, doi: 10.3390/nu13082564.
- [15] A. Mobasheri, Y. Henrotin, H.-K. Biesalski, and M. Shakibaei, "Scientific Evidence and Rationale for the Development of Curcumin and Resveratrol as Nutraceuticals for Joint Health," *IJMS*, vol. 13, no. 4, pp. 4202–4232, Mar. 2012, doi: 10.3390/ijms13044202.
- [16] R. Duggleby, R. D. Danby, J. A. Madrigal, and A. Saudemont, "Clinical Grade Regulatory CD4+ T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies," *Front. Immunol.*, vol. 9, no. 2, Feb. 2018, doi: 10.3389/fimmu.2018.00252.
- [17] M. A. Islam, M. A. Kamal, S. H. Gan, M. Solayman, M. I. Khalil, and F. Alam, "Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases," *Oxidative Medicine and Cellular Longevity*, vol. 2016, no. 48, pp. 1–25, Jan. 2016, doi: 10.1155/2016/5137431.
- [18] V. Zoi, V. Galani, G. D. Lianos, S. Voulgaris, A. P. Kyritsis, and G. A. Alexiou, "The Role of Curcumin in Cancer Treatment," *Biomedicines*, vol. 9, no. 9, p. 1086, Aug. 2021, doi: 10.3390/biomedicines9091086.
- [19] S. Mohammadian Haftcheshmeh, A. Mohammadi, A. Khosrojerdi, S. Lotfi, A. Aliabadi, and A. A. Momtazi-Borojeni, "Immunomodulatory Effects of Curcumin in Rheumatoid Arthritis: Evidence from Molecular Mechanisms to Clinical Outcomes," *Reviews of physiology, biochemistry and pharmacology*, vol. 179, pp. 1–29, Jan. 2020, doi: 10.1007/112_2020_54.
- [20] Y.-P. Chang et al., "Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy," *J. Cell. Physiol.*, vol. 230, no. 7, pp. 1567–1579, Mar. 2015, doi: 10.1002/jcp.24903.
- [21] J. Mlcek, J. Sochor, T. Jurikova, and S. Skrovankova, "Quercetin and Its Anti-Allergic Immune Response," *Molecules*, vol. 21, no. 5, p. 623, May 2016, doi: 10.3390/molecules21050623.
- [22] Y. Wang et al., "The Effects of Berberine on Concanavalin A-Induced Autoimmune Hepatitis (AIH) in Mice and the Adenosine 5'-Monophosphate (AMP)-Activated Protein Kinase (AMPK) Pathway," *Med Sci Monit*, vol. 23, pp. 6150–6161, Dec. 2017, doi: 10.12659/msm.907377.
- [23] L. Müller and S. Di Benedetto, "Neuroimmune crosstalk in chronic neuroinflammation: microglial interactions and immune modulation," *Front. Cell. Neurosci.*, vol. 19, Apr. 2025, doi: 10.3389/fncel.2025.1575022.
- [24] S. M. Awad et al., "Efficacy of curcumin-selenium nanoemulsion in alleviating oxidative damage induced by aluminum chloride in a rat model of Alzheimer's disease," *J Mol Histol*, vol. 56, no. 2, Mar. 2025, doi: 10.1007/s10735-025-10406-6.
- [25] C.-Y. Cheng et al., "Epigallocatechin-3-Gallate-Loaded Liposomes Favor Anti-Inflammation of Microglia Cells and Promote Neuroprotection," *IJMS*, vol. 22, no. 6, p. 3037, Mar. 2021, doi: 10.3390/ijms22063037.

- [26] P. Luo *et al.*, "Immunomodulatory role of T helper cells in rheumatoid arthritis," *Bone & Joint Research*, vol. 11, no. 7, pp. 426–438, July 2022, doi: 10.1302/2046-3758.117.bjr-2021-0594.r1.
- [27] Y. Xu and L. Liu, "Curcumin alleviates macrophage activation and lung inflammation induced by influenza virus infection through inhibiting the NF- κ B signaling pathway.," *Influenza Res Viruses*, vol. 11, no. 5, pp. 457–463, July 2017, doi: 10.1111/irv.12459.
- [28] M. Tang *et al.*, "Pharmacological Aspects of Natural Quercetin in Rheumatoid Arthritis," *DDDT*, vol. 16, no. 10055, pp. 2043–2053, June 2022, doi: 10.2147/dddt.s364759.
- [29] Q. Ma *et al.*, "Reshaping the Inflammatory Environment in Rheumatoid Arthritis Joints by Targeting Delivery of Berberine with Platelet-Derived Extracellular Vesicles," *Advanced NanoBiomed Research*, vol. 1, no. 11, p. 2100071, Aug. 2021, doi: 10.1002/anbr.202100071.
- [30] A. Kuryłowicz and K. Koźniewski, "Anti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes," *Molecules*, vol. 25, no. 9, p. 2224, May 2020, doi: 10.3390/molecules25092224.
- [31] M. Hoca, E. Becer, and H. S. Vatansever, "The role of resveratrol in diabetes and obesity associated with insulin resistance," *Archives of Physiology and Biochemistry*, vol. 129, no. 2, pp. 555–561, Mar. 2021, doi: 10.1080/13813455.2021.1893338.
- [32] R. H. X. Wong and P. R. C. Howe, "Resveratrol Counteracts Insulin Resistance—Potential Role of the Circulation," *Nutrients*, vol. 10, no. 9, p. 1160, Aug. 2018, doi: 10.3390/nu10091160.
- [33] S. Qin *et al.*, "AMPK and its Activator Berberine in the Treatment of Neurodegenerative Diseases.," *CPD*, vol. 26, no. 39, pp. 5054–5066, May 2020, doi: 10.2174/1381612826666200523172334.
- [34] M. Garcia-Alloza, B. J. Bacskaï, L. A. Borrelli, B. T. Hyman, and A. Rozkalne, "Curcumin labels amyloid pathology *in vivo*, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model," *Journal of Neurochemistry*, vol. 102, no. 4, pp. 1095–1104, Mar. 2007, doi: 10.1111/j.1471-4159.2007.04613.x.
- [35] X. Zhu, C. Wu, S. Qiu, X. Yuan, and L. Li, "Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis," *Nutr Metab (Lond)*, vol. 14, no. 1, Sept. 2017, doi: 10.1186/s12986-017-0217-z.
- [36] B. Zhang *et al.*, "Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3.," *Endocrine*, vol. 62, no. 3, pp. 576–587, Aug. 2018, doi: 10.1007/s12020-018-1689-y.
- [37] S.-I. Sohn *et al.*, "Biomedical Applications and Bioavailability of Curcumin – An Updated Overview," *Pharmaceutics*, vol. 13, no. 12, p. 2102, Dec. 2021, doi: 10.3390/pharmaceutics13122102.
- [38] S.-I. Sohn *et al.*, "Biomedical Applications and Bioavailability of Curcumin – An Updated Overview," *Pharmaceutics*, vol. 13, no. 12, p. 2102, Dec. 2021, doi: 10.3390/pharmaceutics13122102.